Search Results - "Salih, Zena"

Oestradiol measurement during fulvestrant treatment for breast cancer by Owen, Laura J., Monaghan, Phillip J., Armstrong, Anne, Keevil, Brian G., Higham, Claire, Salih, Zena, Howell, Sacha

“…Biochemical evaluation of menopausal status is used to inform treatment decisions, including clinical trial eligibility in women with oestrogen receptor…”
Get full text

Home Parenteral Nutrition in Patients with Advanced Cancer: Quality Outcomes from a Centralized Model of Care Delivery by Kopczynska, Maja, Teubner, Antje, Abraham, Arun, Taylor, Michael, Bond, Ashley, Clamp, Andrew, Wight, Rebecca, Salih, Zena, Hasan, Jurjees, Mitchell, Claire, Jayson, Gordon C, Lal, Simon

“…Lack of expertise in home parenteral nutrition (HPN) management has been reported as a barrier to its initiation in patients with advanced cancer (AC), and…”
Get full text

Prognostic factors for mortality with fungal blood stream infections in patients with hematological and non-hematological malignancies by Salih, Zena, Cavet, Jim, Dennis, Mike, Somervaille, Tim, Bloor, Adrian, Kulkarni, Samar

“…Abstract Background: This single center retrospective analysis was undertaken to identify the incidence, clinical impact, and prognostic factors for mortality…”
Get full text

Personalising Immunotherapy in Early and Advanced Stage Melanoma by Salih, Zena

“…Introduction: Melanoma is a paradigm of how the treatment landscape can be revolutionised over a decade. The advent of immune checkpoint blockade (ICB) has…”
Get full text

Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy by Valpione, Sara, Galvani, Elena, Tweedy, Joshua, Mundra, Piyushkumar A, Banyard, Antonia, Middlehurst, Philippa, Barry, Jeff, Mills, Sarah, Salih, Zena, Weightman, John, Gupta, Avinash, Gremel, Gabriela, Baenke, Franziska, Dhomen, Nathalie, Lorigan, Paul C, Marais, Richard

“…Our understanding of how checkpoint inhibitors (CPI) affect T cell evolution is incomplete, limiting our ability to achieve full clinical benefit from these…”
Get full text

Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres by Chan, Joachim, Adderley, Helen, Alameddine, Manal, Armstrong, Anne, Arundell, Donna, Fox, Rosalyn, Harries, Matthew, Lim, Jonathan, Salih, Zena, Tetlow, Christine, Wong, Helen, Thorp, Nicola

“…Purpose Taxane chemotherapy is commonly used in the management of breast cancer. Hair loss (alopecia) is an expected side effect which may have a significant…”
Get full text

T cell immune awakening in response to immunotherapy is age-dependent by Salih, Zena, Banyard, Antonia, Tweedy, Joshua, Galvani, Elena, Middlehurst, Philippa, Mills, Sarah, Weightman, John, Gupta, Avinash, Lorigan, Paul C., Zhou, Cong, Dhomen, Nathalie, Valpione, Sara, Marais, Richard

“…Precision immuno-oncology approaches are needed to improve cancer care. We recently demonstrated that in patients with metastatic melanoma, an increase of…”
Get full text

Tumour infiltrating B cells discriminate checkpoint blockade-induced responses by Valpione, Sara, Campana, Luca G., Weightman, John, Salih, Zena, Galvani, Elena, Mundra, Piyushkumar A., De Rosa, Francesco, Gupta, Avinash, Serra-Bellver, Patricio, Lorigan, Paul, Germetaki, Theodora, Dynowski, Marek, Kitcatt, Stephen, Sahoo, Sudhakar, Lee, Dave, Dhomen, Nathalie, Lord, Graham, Marais, Richard

“…Immune cell-driven anti-cancer activity is paramount for effective responses to checkpoint inhibitors (ICB). However, the contribution of the different immune…”
Get full text

Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene by Morgan, Robert D., Burghel, George J., Flaum, Nicola, Schlecht, Helene, Clamp, Andrew R., Hasan, Jurjees, Mitchell, Claire, Salih, Zena, Moon, Sarah, Hogg, Martin, Lord, Rosemary, Forde, Claire, Lalloo, Fiona, Woodward, Emma R., Crosbie, Emma J., Taylor, Stephen S., Jayson, Gordon C., Evans, D. Gareth R.

“…The prevalence of germline pathogenic variants (PVs) in homologous recombination repair (HRR) and Lynch syndrome (LS) genes in ovarian cancer (OC) is…”
Get full text

Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial by Murphy, Alexander D, Porter, Catharine, White, Ann, Irving, Alys, Adams, Richard, Ray, Ruby, Casbard, Angela, Mahmood, Reem D, Karanth, Suman, Zhou, Cong, Pugh, Julia, Wheeler, Chelsey, Roberts, Victoria, Arnetoli, Giorgio, Salih, Zena, Hasan, Jurjees, Mitchell, Claire, Morgan, Robert D, Clamp, Andrew R, Jayson, Gordon C

“…Cytotoxic chemotherapy for ovarian cancer can be augmented by co-administration of vascular endothelial growth factor inhibitors but these are contraindicated…”
Get more information

BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing? by Morgan, Robert D., Burghel, George J., Flaum, Nicola, Bulman, Michael, Smith, Philip, Clamp, Andrew R., Hasan, Jurjees, Mitchell, Claire L., Salih, Zena, Woodward, Emma R., Lalloo, Fiona, Crosbie, Emma J., Edmondson, Richard J., Wallace, Andrew J., Jayson, Gordon C., Evans, D. Gareth R.

“…National guidelines recommend testing all cases of non-mucinous epithelial ovarian cancer (NMEOC) for germline (blood) and somatic (tumour) BRCA1 / 2…”
Get full text

Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial by Morgan, Robert D, Clamp, Andrew R, White, Daniel J, Price, Marcus, Burghel, George J, Ryder, W David J, Mahmood, Reem D, Murphy, Alexander D, Hasan, Jurjees, Mitchell, Claire L, Salih, Zena, Wheeler, Chelsey, Buckley, Emma, Truelove, Joanna, King, Georgia, Ainaoui, Yasmina, Bhaskar, Sanjeev S, Shaw, Joseph, Evans, D Gareth R, Kilerci, Bedirhan, Pearce, Simon P, Brady, Gerard, Dive, Caroline, O'Connor, James P B, Wallace, Andrew J, Rothwell, Dominic G, Edmondson, Richard J, Jayson, Gordon C

“…A single maintenance course of a PARP inhibitor (PARPi) improves progression-free survival (PFS) in germline BRCA1/2-mutant high-grade serous ovarian cancer…”
Get full text

Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer by Morgan, Robert D, Burghel, George J, Flaum, Nicola, Bulman, Michael, Smith, Philip, Clamp, Andrew R, Hasan, Jurjees, Mitchell, Claire, Salih, Zena, Woodward, Emma R, Lalloo, Fiona, Shaw, Joseph, Desai, Sudha, Crosbie, Emma J, Edmondson, Richard J, Schlecht, Helene, Wallace, Andrew J, Jayson, Gordon C, Evans, D Gareth R

“…Clinical guidelines recommend testing both germline and tumour DNA for pathogenic variants (PVs) in non-mucinous high-grade epithelial ovarian cancer (NMEOC)…”
Get more information

Real-World Concordance between Germline and Tumour IBRCA1/2/I Status in Epithelial Ovarian Cancer by Morgan, Robert D, Burghel, George J, Schlecht, Helene, Clamp, Andrew R, Hasan, Jurjees, Mitchell, Claire L, Salih, Zena, Shaw, Joseph, Desai, Sudha, Jayson, Gordon C, Woodward, Emma R, Evans, D. Gareth R

“…Approximately 10–15% of patients with epithelial ovarian cancer have an inherited (germline) BRCA1 or BRCA2 mutation. Following a diagnosis of epithelial…”
Get full text

Real-World Concordance between Germline and Tumour BRCA1/2 Status in Epithelial Ovarian Cancer by Morgan, Robert D, Burghel, George J, Schlecht, Helene, Clamp, Andrew R, Hasan, Jurjees, Mitchell, Claire L, Salih, Zena, Shaw, Joseph, Desai, Sudha, Jayson, Gordon C, Woodward, Emma R, Evans, D Gareth R

“…Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour / testing followed by germline testing in patients with a positive tumour test…”
Get full text

Increased risk of breast cancer in neurofibromatosis type 1: current insights by Howell, Sacha J, Hockenhull, Kimberley, Salih, Zena, Evans, D Gareth

“…Neurofibromatosis type 1 (NF1) is an autosomal dominant condition caused by mutation/deletion of the gene. The gene product, neurofibromin, is a tumor…”
Get full text

Prognostic significance of neutrophil to lymphocyte ratio (NLR) in patients with resectable oesophageal/gastroesophageal junction (O/GOJ) adenocarcinoma undergoing perioperative chemotherapy by Salih, Zena, Papaxoinis, George, Conway, Alicia, Patrao, Ana Sofia Jardim, Fletcher, Kimberly, Noble, Robert, Owen-Holt, Vikki, Mansoor, Wasat

“…Abstract only…”
Get full text

Thymoma and thymic carcinoma case series: The Christie Hospital by Conway, Alicia, Fletcher, Kimberly, Mohammed, Raees, Salih, Zena, Romanidou, Ourania, Papaxoinis, George, Harris, Margaret, Summers, Yvonne J.

“…Abstract only…”
Get full text

Is Reflex Germline IBRCA1/2/I Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older? by Morgan, Robert D, Burghel, George J, Flaum, Nicola, Bulman, Michael, Smith, Philip, Clamp, Andrew R, Hasan, Jurjees, Mitchell, Claire L, Salih, Zena, Woodward, Emma R, Lalloo, Fiona, Crosbie, Emma J, Edmondson, Richard J, Schlecht, Helene, Jayson, Gordon C, Evans, D. Gareth R

“…Approximately 15% of patients diagnosed with high-grade non-mucinous epithelial ovarian cancer (EOC) have a germline BRCA1/2 mutation, although all patients…”
Get full text

Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? by Paglialunga, Luca, Salih, Zena, Ricciuti, Biagio, Califano, Raffaele

“…Small cell lung cancer (SCLC) is a very aggressive disease, characterised by rapid growth, high response rates to both chemotherapy and radiotherapy and…”
Get full text